AAV
MCID: ANC002
MIFTS: 46

Anca-Associated Vasculitis (AAV)

Categories: Cardiovascular diseases, Gastrointestinal diseases, Immune diseases, Rare diseases

Aliases & Classifications for Anca-Associated Vasculitis

MalaCards integrated aliases for Anca-Associated Vasculitis:

Name: Anca-Associated Vasculitis 53
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 53 73
Antineutrophil Cytoplasmic Antibody-Associated Vasculitis 53
Aav 53

Classifications:



External Ids:

UMLS 73 C2717865

Summaries for Anca-Associated Vasculitis

NIH Rare Diseases : 53 Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of diseases (granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis and microscopic polyangiitis), characterized by destruction and inflammation of small vessels. The clinical signs vary and affect several organs, such as the kidney, stomach, intestine, and lung. Skin lesions, such as purpura and urticaria, result when blood from small vessels leaks under the skin. AAV occurs when neutrophils attack small and medium vessels of the body. The underlying reason for this remains unclear. Treatment includes cyclophosphamide,  glucocorticoids and other autoimmune drugs such as rituximab. 

MalaCards based summary : Anca-Associated Vasculitis, also known as anti-neutrophil cytoplasmic antibody-associated vasculitis, is related to vasculitis and rapidly progressive glomerulonephritis. An important gene associated with Anca-Associated Vasculitis is MPO (Myeloperoxidase), and among its related pathways/superpathways are Innate Immune System and Allograft rejection. The drugs alemtuzumab and Azathioprine have been mentioned in the context of this disorder. Affiliated tissues include neutrophil, kidney and lung.

Related Diseases for Anca-Associated Vasculitis

Diseases related to Anca-Associated Vasculitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 381)
# Related Disease Score Top Affiliating Genes
1 vasculitis 31.7 MPO PRTN3 SERPINA1 TNF
2 rapidly progressive glomerulonephritis 30.2 MPO PRTN3
3 granulocytopenia 30.2 MPO TNF
4 graves' disease 30.2 CTLA4 HLA-DRB1 MPO
5 polyarteritis nodosa 30.2 IL6 MPO PRTN3
6 acute respiratory distress syndrome 30.1 IL6 TNF
7 arthritis 30.1 HLA-DRB1 IL6 TNF
8 pneumonia 30.1 IL6 MPO TNF
9 hyperthyroidism 30.0 CTLA4 GHRL PRTN3
10 granulomatosis with polyangiitis 29.9 CTLA4 HMGB1 MPO PRTN3 SERPINA1
11 temporal arteritis 29.8 HLA-DRB1 IL6 TNF
12 autoimmune disease 29.8 CTLA4 HLA-DRB1 IL6 TNF
13 microscopic polyangiitis 29.7 HLA-DRB1 MPO TNF
14 aplastic anemia 29.7 HLA-DRB1 IL6 TNF
15 ischemic heart disease 29.6 IL6 TNF
16 common variable immunodeficiency 29.6 CTLA4 IL6 TNF
17 lung disease 29.6 IL6 MPO PRTN3 SERPINA1 TNF
18 rheumatoid arthritis 29.6 CTLA4 HLA-DRB1 HMGB1 IL6 PRTN3 TNF
19 mixed connective tissue disease 29.5 HLA-DRB1 IL6 TNF
20 connective tissue disease 29.5 HLA-DRB1 IL6 TNF
21 ulcerative colitis 29.5 IL6 MPO PRTN3 TNF
22 colitis 29.4 CTLA4 IL6 MPO TNF
23 systemic lupus erythematosus 29.3 CTLA4 HLA-DRB1 HMGB1 IL6 MPO PRTN3
24 cholangitis 29.0 HLA-DRB1 IL6 PRTN3 TNF
25 glomerulonephritis 10.5
26 otitis media 10.4
27 aortitis 10.3
28 hemophilia b 10.3
29 influenza 10.3
30 lupus erythematosus 10.3
31 kawasaki disease 10.3
32 epileptic encephalopathy, childhood-onset 10.3 MPO PRTN3
33 scleroderma, familial progressive 10.2
34 pulmonary fibrosis 10.2
35 monoclonal paraproteinemia 10.2 MPO PRTN3
36 muscular dystrophy 10.2
37 chronic orbital inflammation 10.2 CTLA4 PRTN3
38 chronic maxillary sinusitis 10.2 MPO PRTN3
39 anterior scleritis 10.2 MPO PRTN3
40 pulmonary hemosiderosis 10.2 MPO PRTN3
41 stroke, ischemic 10.2
42 respiratory failure 10.2
43 crescentic glomerulonephritis 10.2
44 interstitial lung disease 10.2
45 diffuse alveolar hemorrhage 10.2
46 arteritic anterior ischemic optic neuropathy 10.2 MPO PRTN3
47 achromatopsia 10.2
48 glycogen storage disease 10.2
49 type 1 diabetes mellitus 12 10.2 CTLA4 HLA-DRB1
50 autoimmune addison disease 10.2 CTLA4 HLA-DRB1

Graphical network of the top 20 diseases related to Anca-Associated Vasculitis:



Diseases related to Anca-Associated Vasculitis

Symptoms & Phenotypes for Anca-Associated Vasculitis

Drugs & Therapeutics for Anca-Associated Vasculitis

Drugs for Anca-Associated Vasculitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 105)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
alemtuzumab Approved, Investigational Phase 4 216503-57-0
2
Azathioprine Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 446-86-6 2265
3
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
4
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 302-25-0
5
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3,Not Applicable 2921-57-5
6
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 50-24-8 5755
7
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 53-03-2 5865
8
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 83-43-2 6741
9
leucovorin Approved Phase 4,Phase 3,Phase 2 58-05-9 6006 143
10
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
11
Methotrexate Approved Phase 4,Phase 3,Phase 2 59-05-2, 1959-05-2 126941
12
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
13
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 59-30-3 6037
14
Prednisolone hemisuccinate Experimental Phase 4,Phase 2,Phase 3,Not Applicable 2920-86-7
15 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Not Applicable
16 Alkylating Agents Phase 4,Phase 3,Phase 2,Not Applicable
17 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2
21 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
22 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Not Applicable
23 Prednisolone acetate Phase 4,Phase 2,Phase 3,Not Applicable
24 glucocorticoids Phase 4,Phase 2,Phase 3,Not Applicable
25 Hormone Antagonists Phase 4,Phase 2,Phase 3,Not Applicable
26 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Not Applicable
27 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Not Applicable
28 Hormones Phase 4,Phase 2,Phase 3,Not Applicable
29 Methylprednisolone acetate Phase 4,Phase 2,Phase 3,Not Applicable
30 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Not Applicable
31 Vitamin B9 Phase 4,Phase 3,Phase 2
32 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Neuroprotective Agents Phase 4,Phase 2,Phase 3,Not Applicable
34 Antitubercular Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Antiemetics Phase 4,Phase 2,Phase 3,Not Applicable
36 Vitamin B Complex Phase 4,Phase 3,Phase 2
37 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Not Applicable
39 Folic Acid Antagonists Phase 4,Phase 3,Phase 2
40 Dermatologic Agents Phase 4,Phase 3,Phase 2,Not Applicable
41 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Protective Agents Phase 4,Phase 2,Phase 3,Not Applicable
43 Autonomic Agents Phase 4,Phase 2,Phase 3,Not Applicable
44 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
45 Folate Phase 4,Phase 3,Phase 2
46 Immunoglobulins Phase 4,Phase 2,Phase 3,Not Applicable
47 Antibodies, Antineutrophil Cytoplasmic Phase 4,Phase 3,Phase 2,Not Applicable
48 Antibodies Phase 4,Phase 2,Phase 3,Not Applicable
49 Tin Fluorides Phase 4,Phase 3
50
belimumab Approved Phase 3 356547-88-1 5957 10451420

Interventional clinical trials:

(show top 50) (show all 119)
# Name Status NCT ID Phase Drugs
1 Alemtuzumab for ANCA Associated Refractory Vasculitis Unknown status NCT01405807 Phase 4 Alemtuzumab
2 CHUSPAN SCS BP Treatment of Churg–Strauss Syndrome Without Poor-Prognosis Factors Unknown status NCT00399399 Phase 4 azathioprine;cyclophosphamide
3 CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors Unknown status NCT00400075 Phase 4 azathioprine;cyclophosphamide
4 Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis Completed NCT02169219 Phase 4 Glucocorticoids;Rituximab
5 Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Completed NCT00307671 Phase 4 prednisone, methylprednisolone,cyclophosphamides;Cyclophosphamide, Azathioprine,prednisone,methylprednisolone;Mycophenolate mofetil,methotrexate
6 Low-dose Glucocorticoid Vasculitis Induction Study Recruiting NCT02198248 Phase 4 Rituximab;Glucocorticoids
7 Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing Recruiting NCT02749292 Phase 4 Rituximab
8 Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. Recruiting NCT03164473 Phase 4 Rituximab;Azathioprine;Placebo-rituximab;Placebo-azathioprine
9 A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis Suspended NCT02115997 Phase 4 Methylprednisolone;Prednisone;Rituximab
10 Prevention of Relapses in Proteinase 3 (PR3)-Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis Terminated NCT00128895 Phase 4 azathioprine
11 Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis Terminated NCT02626845 Phase 4 Rituximab
12 Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD") Terminated NCT00747461 Phase 4
13 WEGENT - Comparison of Methotrexate or Azathioprine as Maintenance Therapy for ANCA-Associated Vasculitides Unknown status NCT00349674 Phase 3 Azathioprine: 2 mg/kg/day;methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week
14 Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA) Unknown status NCT00103792 Phase 3 mycophenolate mofetil;cyclophosphamide
15 Efficacy and Safety of E-101 Solution for Preventing Surgical Site Infections After Colorectal Surgery Unknown status NCT01297959 Phase 3 E-101 Solution 300 GU/ml;Saline solution
16 Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis Completed NCT01731561 Phase 3 Rituximab (Arm B);Rituximab (Arm A)
17 Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides Completed NCT00430105 Phase 2, Phase 3 cyclophosphamide
18 Efficacy Study of Two Treatments in the Remission of Vasculitis Completed NCT00748644 Phase 3 Rituximab;Azathioprine
19 Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis Completed NCT00104299 Phase 2, Phase 3 Rituximab plus cyclophosphamide placebo (rituximab group);Cyclophosphamide plus rituximab placebo (control group);Azathioprine;Methylprednisolone (or other glucocorticoid);Prednisone
20 Clinical Trial of Mycophenolate Versus Cyclophosphamide in ANCA Vasculitis Completed NCT00414128 Phase 2, Phase 3 mycophenolate mofetil;cyclophosphamide
21 Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis Completed NCT00987389 Phase 3 Glucocorticoids
22 A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis Completed NCT02020889 Phase 3 Placebo
23 Belimumab in Remission of VASculitis Completed NCT01663623 Phase 3 Azathioprine
24 Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) Completed NCT00647166 Phase 3 corticosteroid and azathioprine;corticosteroid and placebo
25 Etanercept for Wegener's Granulomatosis Completed NCT00005007 Phase 2, Phase 3 Etanercept
26 Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Completed NCT00138983 Phase 3 Alendronate versus alfacalcidol (1-alpha OH vitamin D)
27 Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease Recruiting NCT03323476 Phase 3 Maintenance (or initiation) of immunosuppressive treatment: Imurel®, Mabthera®,Cellcept®, Cortancyl®
28 Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's) Recruiting NCT02108860 Phase 3 Abatacept;placebo
29 The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach Recruiting NCT01933724 Phase 3 5 mg prednisone;0 mg prednisone
30 The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach Recruiting NCT01940094 Phase 3 5 mg Prednisone;0 mg Prednisone
31 Rituximab in Eosinophilic Granulomatosis With Polyangiitis Recruiting NCT02807103 Phase 3 Rituximab;Placebo-rituximab;Cyclophosphamide;Placebo-cyclophosphamide
32 A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis Active, not recruiting NCT02994927 Phase 3 CCX168;Prednisone;Cyclophosphamide;Azathioprine
33 Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab Active, not recruiting NCT02433522 Phase 3 rituximab;Placebo
34 Rituximab Vasculitis Maintenance Study Active, not recruiting NCT01697267 Phase 3 Azathioprine
35 Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921 Active, not recruiting NCT03298061 Phase 3 Mepolizumab;Prednisolone
36 The Effect of Some Drugs Used in Treatment of Vasculitis on the Complement System in Children Not yet recruiting NCT03692416 Phase 3 Ibuprofen;Prednisone;Methotrexate
37 IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis Terminated NCT00307645 Phase 3 Cyclophosphamide;Mycophenolate mofetil;Azathioprine;Prednisone (and methylprednisolone)
38 Intravenous Immunoglobulin After Relapse in Vasculitis Terminated NCT00307658 Phase 3 Intravenous immunoglobulins (human immunoglobulins G)
39 Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis Terminated NCT01446211 Phase 3 Gusperimus + glucocorticoids;cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids
40 Plasma Exchange for Renal Vasculitis Terminated NCT01408836 Phase 2, Phase 3 Intravenous methyl prednisolone;Methyl prednisolone
41 CMV Modulation of the Immune System in ANCA-associated Vasculitis Unknown status NCT01633476 Phase 2 Valaciclovir
42 Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides Unknown status NCT00751517 Phase 2 Methotrexate;Cyclophosphamide
43 Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis Completed NCT02222155 Phase 2 CCX168 low dose plus standard of care;CCX168 high dose plus standard of care
44 A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis Completed NCT01363388 Phase 2 Placebo;CCX168
45 Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis Completed NCT00293072 Phase 2 Rituximab
46 Anti-Cytokine Therapy for Vasculitis Completed NCT00753103 Phase 2 Cyclophosphamide;Prednisolone;Azathioprine;Mycophenolate mofetil;Methylprednisolone
47 Safety and Efficacy Study of Mepolizumab in Churg Strauss Syndrome Completed NCT00716651 Phase 2 mepolizumab
48 Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome Completed NCT00527566 Phase 1, Phase 2
49 Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis Completed NCT00530075 Phase 2 Gusperimus
50 A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis Completed NCT01750697 Phase 2 Rituximab

Search NIH Clinical Center for Anca-Associated Vasculitis

Genetic Tests for Anca-Associated Vasculitis

Anatomical Context for Anca-Associated Vasculitis

MalaCards organs/tissues related to Anca-Associated Vasculitis:

41
Neutrophil, Kidney, Lung, Skin, B Cells, T Cells, Endothelial

Publications for Anca-Associated Vasculitis

Articles related to Anca-Associated Vasculitis:

(show top 50) (show all 781)
# Title Authors Year
1
An Autopsy Case of Myeloperoxidase-anti-neutrophil Cytoplasmic Antibody (MPO-ANCA) -associated Vasculitis Accompanied by Cryoglobulinemic Vasculitis Affecting the Kidneys, Skin, and Gastrointestinal Tract. ( 29709950 )
2018
2
The adenosinergic system: a potential player in the pathogenesis of ANCA-associated vasculitis? ( 29745882 )
2018
3
Letter to the Editor: Time for cost-effectiveness studies for preventive strategies applied according to risk of cytomegalovirus-related morbidity and mortality in ANCA-associated vasculitis. ( 29663157 )
2018
4
Anti-neutrophil extracellular trap antibody in a patient with relapse of anti-neutrophil cytoplasmic antibody-associated vasculitis: a case report. ( 29929470 )
2018
5
The treatment outcomes of rituximab for intractable otitis media with ANCA-associated vasculitis. ( 29885746 )
2018
6
Excessive neutrophil extracellular trap formation in ANCA-associated vasculitis is independent of ANCA. ( 29606398 )
2018
7
Myeloperoxidase-ANCA-positive granulomatosis with polyangiitis is a distinct subset of ANCA-associated vasculitis: A retrospective analysis of 455 patients from a single center in China. ( 29887327 )
2018
8
Sweet's Syndrome Mimicking ANCA-Associated Vasculitis. ( 29355513 )
2018
9
PR3-ANCA: a potential biomarker of disease activity for propylthiouracil-induced ANCA-associated vasculitis. ( 29888703 )
2018
10
Cocaine and ANCA associated vasculitis-like syndromes - A case series. ( 29108823 )
2018
11
The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis. ( 29371340 )
2018
12
Avacopan in the treatment of ANCA-associated vasculitis. ( 29718732 )
2018
13
Late-onset Pneumocystis jirovecii pneumonia (PJP) in patients with ANCA-associated vasculitis. ( 29808456 )
2018
14
Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire. ( 29695498 )
2018
15
Delta Neutrophil Index Is Associated with Vasculitis Activity and Risk of Relapse in ANCA-Associated Vasculitis. ( 29611402 )
2018
16
ANCA associated vasculitis in patients from Saudi Arabia. ( 29643885 )
2018
17
ANCA-associated Vasculitis in a Case of Congenital Leptin Deficiency. ( 29937567 )
2018
18
Health-related quality of life in ANCA-associated vasculitis and item generation for a disease-specific patient-reported outcome measure. ( 29379322 )
2018
19
Correction to: Late-onset Pneumocystis jirovecii pneumonia (PJP) in patients with ANCA-associated vasculitis. ( 29971582 )
2018
20
Correction: Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): protocol for a multicentre, open-label, randomised controlled trial. ( 29358455 )
2018
21
Methimazole-induced ANCA-associated vasculitis with diffuse alveolar haemorrhage. ( 29760925 )
2018
22
Rituximab induction therapy for de novo ANCA associated vasculitis in pregnancy: a case report. ( 29954345 )
2018
23
Rituximab in ANCA-associated vasculitis: fewer infusions or ultra low-dose maintenance therapy? ( 29921573 )
2018
24
Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). ( 29695500 )
2018
25
Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study. ( 29902982 )
2018
26
Exploring sex-specific differences in the presentation and outcomes of ANCA-associated vasculitis: a nationwide registry-based cohort study. ( 29790004 )
2018
27
Seasonal variations in the onset of positive and negative renal ANCA-associated vasculitis in Spain. ( 30094010 )
2018
28
ANCA associated vasculitis: experience of a tertiary care referral center. ( 30095143 )
2018
29
Response to: 'Role of tubulointerstitial injury in ANCA-associated vasculitis is underestimated' by Moiseev et al. ( 30100559 )
2018
30
Subclinical reactivation of cytomegalovirus drives CD4+CD28null T-cell expansion and impaired immune response to pneumococcal vaccination in ANCA-associated vasculitis. ( 30102389 )
2018
31
ANCA-associated vasculitis in scleroderma: A renal perspective
. ( 30106367 )
2018
32
B cell therapy in ANCA-associated vasculitis: current and emerging treatment options. ( 30108367 )
2018
33
The host cellular immune response to cytomegalovirus targets the endothelium and is associated with increased arterial stiffness in ANCA-associated vasculitis. ( 30157919 )
2018
34
Low serum complement 3 level is associated with severe ANCA-associated vasculitis at diagnosis. ( 30168048 )
2018
35
Muscle weakness as a presenting symptom in ANCA-associated vasculitis. ( 30185364 )
2018
36
Targeted immunotherapy strategies in ANCA-associated vasculitis. ( 30201478 )
2018
37
Systemic immune-inflammation index could estimate the cross-sectional high activity and the poor outcomes in immunosuppressive drug-naïve patients with ANCA-associated vasculitis. ( 30203901 )
2018
38
Serum hepcidin is increased in ANCA-associated vasculitis and correlates with activity markers. ( 30204470 )
2018
39
In ANCA-associated vasculitis in remission, tailored vs fixed-schedule rituximab did not differ for relapse at 28 months. ( 30242406 )
2018
40
Differentiation of Cocaine-Induced Midline Destructive Lesions from ANCA-Associated Vasculitis. ( 30245987 )
2018
41
The frequency of ANCA-associated vasculitis in a national database of hospitalized patients in China. ( 30286799 )
2018
42
Subclinical but significant liver fibrosis in patients with ANCA-associated vasculitis. ( 30325303 )
2018
43
Case report: de novo ANCA-associated vasculitis after kidney transplantation treated with rituximab and plasma exchange. ( 30340563 )
2018
44
Calprotectin as a smoldering activity detection tool and renal prognosis biomarker in ANCA associated vasculitis. ( 30347000 )
2018
45
Interstitial lung disease with usual interstitial pneumonia pattern preceding the presentation of ANCA-associated vasculitis by 4 years: coincidence or correlation? ( 30364520 )
2018
46
B cell depletion therapy dampens CD8+ T cell response in ANCA-associated vasculitis. ( 30375745 )
2018
47
Publisher Correction: B cell therapy in ANCA-associated vasculitis: current and emerging treatment options. ( 30390047 )
2018
48
Prognostic Factors for Survival and Relapse in ANCA-Associated Vasculitis with Renal Involvement: A Clinical Long-Term Follow-Up Study. ( 30410799 )
2018
49
Effect of disease activity at three and six months on long-term outcomes in ANCA associated vasculitis. ( 30418705 )
2018
50
Anti-plasminogen antibodies in ANCA-associated vasculitis: An optimized anti-plasminogen assay. ( 30419041 )
2018

Variations for Anca-Associated Vasculitis

Expression for Anca-Associated Vasculitis

Search GEO for disease gene expression data for Anca-Associated Vasculitis.

Pathways for Anca-Associated Vasculitis

Pathways related to Anca-Associated Vasculitis according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.52 CTLA4 HLA-DRB1 HMGB1 IL6 MPO PRTN3
2
Show member pathways
12.58 CTLA4 HLA-DRB1 IL6 TNF
3
Show member pathways
12.19 CTLA4 IL6 TNF
4 12.18 HLA-DRB1 IL6 TNF
5
Show member pathways
12.07 IL6 MPO TNF
6 12 HLA-DRB1 IL6 TNF
7 11.94 HLA-DRB1 IL6 TNF
8
Show member pathways
11.71 HMGB1 IL6 TNF
9 11.64 IL6 MPO TNF
10 11.53 HLA-DRB1 IL6 TNF
11 11.23 IL6 SERPINA1 TNF
12 11.21 CTLA4 HLA-DRB1 IL6 TNF
13 11.14 IL6 TNF
14 11.13 IL6 TNF
15 11.08 IL6 TNF
16 11.06 IL6 TNF
17 11.01 HMGB1 MPO
18 10.84 IL6 TNF
19 10.79 HLA-DRB1 IL6 TNF
20 10.76 IL6 TNF
21 10.66 MPO TNF
22 10.61 HMGB1 IL6 MPO TNF

GO Terms for Anca-Associated Vasculitis

Cellular components related to Anca-Associated Vasculitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.5 GHRL HMGB1 IL6 MPO PRTN3 SERPINA1
2 extracellular space GO:0005615 9.17 GHRL HMGB1 IL6 MPO PRTN3 SERPINA1

Biological processes related to Anca-Associated Vasculitis according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.8 CTLA4 HLA-DRB1 IL6 TNF
2 neutrophil degranulation GO:0043312 9.76 HMGB1 MPO PRTN3 SERPINA1
3 regulation of signaling receptor activity GO:0010469 9.71 GHRL HMGB1 IL6 TNF
4 negative regulation of T cell proliferation GO:0042130 9.59 CTLA4 HLA-DRB1
5 negative regulation of endothelial cell proliferation GO:0001937 9.58 GHRL TNF
6 acute-phase response GO:0006953 9.58 IL6 SERPINA1
7 positive regulation of insulin secretion involved in cellular response to glucose stimulus GO:0035774 9.57 GHRL HLA-DRB1
8 negative regulation of interferon-gamma production GO:0032689 9.56 HLA-DRB1 HMGB1
9 positive regulation of apoptotic process GO:0043065 9.56 CTLA4 HMGB1 IL6 TNF
10 positive regulation of sprouting angiogenesis GO:1903672 9.55 GHRL HMGB1
11 negative regulation of neurogenesis GO:0050768 9.54 IL6 TNF
12 positive regulation of vascular endothelial cell proliferation GO:1905564 9.52 GHRL HMGB1
13 positive regulation of chemokine production GO:0032722 9.51 IL6 TNF
14 positive regulation of glial cell proliferation GO:0060252 9.48 IL6 TNF
15 negative regulation of growth of symbiont in host GO:0044130 9.43 MPO TNF
16 inflammatory response to antigenic stimulus GO:0002437 9.37 HLA-DRB1 HMGB1
17 negative regulation of lipid storage GO:0010888 9.32 IL6 TNF
18 positive regulation of neuroinflammatory response GO:0150078 9.16 IL6 TNF
19 response to glucocorticoid GO:0051384 9.13 HMGB1 IL6 TNF
20 positive regulation of interleukin-6 production GO:0032755 8.8 HMGB1 IL6 TNF

Molecular functions related to Anca-Associated Vasculitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.8 HMGB1 IL6 TNF

Sources for Anca-Associated Vasculitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....